Ceftolozane-tazobactam: A new-generation cephalosporin

American Journal of Health-System Pharmacy

Volumn 72, Issue 24, 2015, Pages 2135-2146

  Cluck, David ^a   Lewis, Paul ^b   Stayer, Brooke ^c   Spivey, Justin ^d   Moorman, Jonathan ^e  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b Johnson City Medical Center   (United States)

^c Pharmacy Services   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e East Tennessee State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CEFTOLOZANE; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ABDOMINAL INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEALTH CARE COST; HUMAN; HYPERSENSITIVITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; REVIEW; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VENTILATOR ASSOCIATED PNEUMONIA; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); MEDICINAL CHEMISTRY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; HUMANS; PENICILLANIC ACID;

EID: 84964045305     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150049     Document Type: Review

References (67)

1. Infectious Diseases Society of America. The 10 by '20 initiative: pursuing global commitment to develop 10 new antimicrobial drugs by 2020. Clin Infect Dis. 2010; 50:1081-3.
2. Boucher HW, Talbot GH, Benjamin DK et al. 10 by '20 progress-development of new drugs active against gram negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013; 56:1685-94.
3. Food and Drug Administration. FDA drug safety communication: FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia (March 6, 2014). www.fda.gov/Drugs/DrugSafety/ucm387971.htm (accessed 2014 Dec 12).
4. Food and Drug Administration. FDA drug safety communication: FDA warns of increased risk of death with iv antibacterial Tygacil (tigecycline) and approves new boxed warning (September 27, 2013). www.fda.gov/drugs/drugsafety/ucm369580.htm (accessed 2014 Dec 12).
5. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother. 2001; 47:247-50.
6. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009; 22:582-610.
7. Murano K, Yamanaka T, Toda A et al. Structural requirements for the stability of novel cephalosporins to AmpC beta lactamase based on 3D-structure. Bioorg Med Chem. 2008; 16:2261-75.
8. Toda A, Ohki H, Yamanaka T et al. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett. 2008; 18:4849-52.
9. Takeda S, Ishii Y, Hatano K et al. Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007; 30:443-5.
10. Drawz SM, Bonomo RA. Three decades of beta lactamase inhibitors. Clin Microbiol Rev. 2010; 23:160-201.
11. Moyá B, Zamorano L, Juan C et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54:3933-7.
12. Moya B, Dotsch A, Juan C et al. Beta lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog. 2009; 5: e1000353.
13. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995; 8:557-84.
14. Brown NP, Pillar CM, Sahm DF et al. Activity profile of CXA-101 and CXA-101/tazobactam against target gram-positive and gram-negative pathogens. Abstract and poster presented at 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2009 Sep 12-15.
15. Zhanel GG, Adam HJ, Baxter M et al. In vitro activity of ceftolozane/tazobactam against 5,715 gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals in 2011 and 2012: CANWARD surveillance study. Abstract presented at 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2012 Sep 9-12.
16. Pillar CM, Sahm D, Brown N et al. Activity profile of CXA-101 against gram-positive and gram-negative pathogens by broth and agar dilution. Abstract and poster presented at 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2008 Oct 25-28.
17. Brown NP, Pillar CM, Sahm DF et al. Disk diffusion testing of CXA-101 and CXA-101 in combination with tazobactam against target pathogens. Abstract and poster presented at 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2009 Sep 12-15.
18. Farrell DJ, Flamm RK, Sader HS et al. Antimicrobial activity of ceftolozane/tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US hospitals (2011-2012). Antimicrob Agents Chemother. 2013; 57:6305-10.
19. Sader HS, Rhomberg PR, Farrell DJ et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011; 55:2390-4.
20. Bulik CC, Christensen H, Nicolau DP. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother. 2010; 54:557-9.
21. Zerbaxa (ceftolozane and tazobactam) package insert. Lexington, MA: Cubist Pharmaceuticals; 2014.
22. Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane/tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2013; 58:1218-23.
23. Takeda S, Nakai T, Wakai Y et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007; 51:826-30.
24. Walkty A, Karlowsky JA, Adam H et al. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007-2012. Antimicrob Agents Chemother. 2013; 57:5707-9.
25. Juan C, Zamorano L, Perez JL et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. 2010; 54:846-51.
26. Sader HS, Farrell DJ, Castanheira M et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-2012). J Antimicrob Chemother. 2014; 69:2713-22.
27. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010; 65:1972-4.
28. Zamorano L, Juan C, Fernández-Olmos A et al. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients. Clin Microbiol Infect. 2010; 16:1482-7.
29. Estabrook M, Bussell B, Clugston SL, Bush K. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases. J Clin Microbiol. 2014; 52:4049-52.
30. Titelman E, Karlsson IM, Ge Y et al. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2011; 70:137-41.
31. Melchers MJ, van Mil CH, Mouton JW. In vitro activity of ceftolozane alone and in combination with tazobactam against extended spectrum beta-lactamase harbouring "Enterobacteriaceae". Abstract presented at 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2012 Sep 9-12.
32. Giske CG, Ge J, Nordmann P. Activity of cephalosporin CXA-101(FR264205) and comparators against extended-spectrum-beta-lactamase-producing Pseudomonas aeruginosa. J Antimicrob Chemother. 2009; 64:430-1.
33. Popejoy MW, Cloutier D, Huntington JA et al. Ceftolozane/tazobactam for the treatment of cUTI and cIAI caused by ESBL-producing Enterobacteriaceae. Abstract presented at IDWeek. Philadelphia, PA; 2014 Oct 8-12.
34. Papp-Wallace KM, Bethel CR, Distler AM et al. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrob Agents Chemother. 2010; 54:890-7.
35. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002; 34:634-40.
36. Rodrigez-Baño J, Dolores Navarro M, Retamar P et al. β-lactam/b-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum b-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012; 54:167-74.
37. Tamma PD, Girdwood S, Gopaul R et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013; 57:781-8.
38. Siedner MJ, Galar A, Guzmán-Suarez BB et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis. 2014; 58:1554-63.
39. Cabot G, Mulet X, Moya B et al. Dynamics and mechanisms of resistance development to ceftazidime, meropenem and ceftolozane/tazobactam in wild-type and mutator P. aeruginosa strains. In: Abstracts: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; American Society for Microbiology; 2012.
40. Moulds N, Lister P. Impact of characterized resistance mechanisms on the susceptibility of Pseudomonas aeruginosa to CXA-101. Abstract and poster presented at 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA; 2010 Sep 12-15.
41. Moore RA, Chan L, Hancock RE. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984; 26:539-45.
42. Gunn JS, Lim KB, Krueger J et al. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol. 1998; 27:1171-82.
43. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005; 49:2479-87.
44. Jalal S, Wretlind B. Mechanisms of quin-olone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist. 1998; 4:257-61.
45. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 2010; 54:3427-31.
46. Miller B, Hershberger E, Benziger D et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012; 56:3086-91.
47. Merrem (meropenem) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals; 2013.
48. Ceftazidime package insert. Research Triangle Park, NC: GlaxoSmithKline; 2007.
49. Cefepime package insert. Lake Forest, IL: Hospira Inc.; 2012.
50. Miller B, Chandorkar G, Umeh O et al. Safety and PK of iv ceftolozane/tazobactam 3 g q8h and cumulative fraction of response in plasma and epithelial lining fluid in a simulated VAP population. In: Abstracts: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2012.
51. Chandorkar G, Huntington JA, Gotfried MH et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012; 67:2463-9.
52. Nau R, Kinzig-Schippers M, Sörgel F et al. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients. Antimicrob Agents Chemother. 1997; 41:987-91.
53. Chandorkar G, Xiao A, Mouksassi MS et al. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol. 2015; 55:230-9.
54. Wooley M, Miller B, Krishna G et al. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother. 2014; 58:2249-55.
55. Vogelman B, Gudmundsson S, Legett J et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988; 158:831-47.
56. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995; 22:89-96.
57. Soon RL, Forrest A, Holden PN et al. In vitro pharmacodynamics of ceftolozane/tazobactam against β-lactamase producing Escherichia coli. In: Abstracts: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2012.
58. Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013; 54:1577-82.
59. Umeh O, Friedland I. A double blind, randomized, phase 2 study to compare the safety and efficacy of intravenous CXA-101 (CXA) and intravenous ceftazidime (CTZ) in complicated urinary tract infections (cUTI). Poster and presentation at 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA; 2010 Sep 12-15.
60. Lucasti C, Hershberger E, Miller B, Yankelev S. Multicenter, double-blind, randomized, phase II trial to assess safety and efficacy of ceftolozane-tazobactam plus metronidazole compared to meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014; 58:5350-7.
61. Wagenlehner F, Umeh O, Huntington J et al. Efficacy and safety of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI) in hospitalized adults: results from the phase 3 ASPECT-cUTI trial. Presentation at 24th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain; 2014 May 10-13.
62. Sakoulas G, Umeh O, Huntington J et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI) caused by levofloxacin-resistant pathogens: results from the cUTI trial. Abstract presented at IDWeek. Philadelphia, PA; 2014 Oct 8-12.
63. Solomkin J, Hershberger E, Miller B et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015; 60:1462-71.
64. Miller B, Popejoy MW, Hershberger E et al. Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a phase 3 ceftolozane/tazobactam study. Abstract presented at IDWeek. Philadelphia, PA; 2014 Oct 8-12.
65. ClinicalTrials.gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). www.clinicaltrials.gov/ct2/show/NCT02070757?term=ceftolozane&rank=1 (accessed 2014 Dec 17).
66. Merck & Co., Inc. Zerbaxa (ceftolozane and tazobactam) product guide for pharmacy. www.zerbaxa.com/pdf/ZERBAXA-Ordering-Dosing.pdf (accessed 2015 Mar 23).
67. Ceftolozane/tazobactam (Zerbaxa)-a new intravenous antibiotic. Med Lett Drugs Ther. 2015; 57:31-3.